



THERAVECTYS & THE INSTITUT PASTEUR EXTEND THE JOINT-LAB

*To capitalize on their licensing agreement and boost synergies THERAVECTYS and the INSTITUT PASTEUR reaffirm their collaborative **JOINT-LAB based on the Lentiviral Vectors Technology.***

PARIS, October, 25, 2019 – THERAVECTYS, a vaccine company that designs and develops safe and highly efficient T-cell vaccines based on a proprietary lentiviral vector platform, announces the consolidation of its long-standing collaboration with the Institut Pasteur through the extension of the R&D Joint-Lab.

Since its incorporation in 2005, through a global and exclusive license granted by the Institut Pasteur to its spin-off created by Dr Pierre Charneau, TheraVectys has controlled, or benefited from, 100% of the rights on lentiviral vectors vaccines. The Joint-Lab between TheraVectys and Institut Pasteur designated under “IPTV” allows an effective synergy between TheraVectys and, the Molecular Virology and Vectorology Unit of the Pasteur Institute, while giving access to numerous technological platforms available in the Pasteur Institute.

“We are honored to pursue this unique collaboration with the prestigious Pasteur Institute” says Jean Chalopin CEO. These first two years of collaboration demonstrate the potential of this platform in terms of value creation and the efficiency of this plural ecosystem. This extension validates this innovative model to leverage at best R&D progress and maintain a sustained innovative pipeline while positioning the Lentiviral Vectors as a breakthrough therapy against cancers and major infectious diseases”

“The IPTV joint Laboratory is unique in the Pasteur Institute (IP). After few months of installation and training of staff, we quickly arrived at a very satisfactory level of scientific production. The quality of the work performed by the IPTV laboratory will lead in the coming months to a series of publications and patent deposits in the infectious field as well as in anti-tumor applications.” says Dr. Pierre Charneau, Head of the Joint-Lab.

The Joint-Lab Agreement has been extended for two years since June 7th, 2019, with a collaborative pipeline of 14 projects i.e 5 additional indications compared to the initial perimeter at IPTV creation date in 2017.

ABOUT THERAVECTYS

THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology. Founded by pioneer inventor Dr. Pierre Charneau, as a spin-off of the Institut Pasteur, TheraVectys leverages a unique proprietary platform to deliver remarkably safe and highly efficient T-cell vaccines as a response to critical unmet medical needs. THERAVECTYS’ technology and worldwide license domain has an almost unlimited number of applications in infectious diseases, virally-induced cancers and cancers, and is probably a major silent revolution in vaccination since the discovery of the vaccine against rabies by Louis Pasteur. Our purpose: ‘profoundly transform global health’. Our approach: strategic industrial partnering for leading our PoC-validated vaccine-candidates to clinical trials and to market.

ABOUT THE INSTITUT PASTEUR AND THE INSTITUT PASTEUR INTERNATIONAL NETWORK

The Institut Pasteur, a private foundation with officially recognized charitable status set up by Louis Pasteur in 1887, is today an internationally renowned center for biomedical research with a network of 33 institutes worldwide. In the pursuit of its mission to prevent and fight against diseases in France and throughout the world, the Institut Pasteur operates in four main areas: scientific and medical research, public health and health monitoring, teaching, and business development and technology transfer.

More than 2,500 people work on its Paris campus. The Institut Pasteur is a globally recognized leader in infectious diseases, microbiology, and immunology. Its 130 units also focus their research on certain cancers, genetic and neurodegenerative diseases, genomics and developmental biology. This research aims to expand our knowledge of living organisms in a bid to lay the foundation for new prevention strategies and novel therapeutics. Since its inception, 10 Institut Pasteur scientists have been awarded the Nobel Prize for Medicine, including two in 2008 for the 1983 discovery of the human immunodeficiency virus (HIV) that causes AIDS.

With a portfolio of 350 patent families, 24 new spin-off companies, and over 170 license/sublicense and research agreements in the fields of diagnostics, vaccines and therapeutics, the Institut Pasteur plays a major role in technology transfer activities that directly benefit patients and generate significant resources to further support its research activities.

For more information

+33 1 43 90 19 20

contact@theravectys.com



THERAVECTYS - Institut Pasteur, Bât P Biotop, 28 rue du Docteur Roux, 75724 Paris Cedex 15, FRANCE - SA Capital: 220 454.5 EUR

www.theravectys.com